We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study to Determine the Safety and Tolerability of 2 Concentrations of QLS-101

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04947124
Recruitment Status : Completed
First Posted : July 1, 2021
Last Update Posted : August 23, 2022
Sponsor:
Information provided by (Responsible Party):
Qlaris Bio, Inc.

Study Description
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
Safety and tolerability study of 2 concentrations of QLS-101 for adult subjects with Sturge Weber Syndrome (SWS)-related glaucoma due to elevated episcleral venous pressure (EVP).

Condition or disease Intervention/treatment Phase
Sturge-Weber Syndrome (SWS) Glaucoma Glaucoma Congenital Ocular Hypertension Drug: QLS-101ophthalmic solution 1% Drug: QLS-101ophthalmic solution 2% Phase 2

Detailed Description:
Masked, randomized, single site, crossover study to compare 2 concentrations of QLS-101. Subjects will be randomized to one of 2 concentrations of QLS-101 for the first 14 days of daily dosing, and after a 14-day washout period they will be crossed over to the other concentration for another 14 days of daily dosing. Dose assignment is masked to patient and investigator.
Study Design
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 3 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Intervention Model Description: Patients take 2 different doses of investigational product at distinct treatment periods. Dose is masked.
Masking: Double (Participant, Investigator)
Masking Description: Masked investigational product labeling.
Primary Purpose: Treatment
Official Title: Masked, Randomized, Single-site, Crossover Study to Determine the Safety and Tolerability of 2 Concentrations of QLS-101 Dosed for 14 Days in Adult Subjects With Sturge-Weber Syndrome (SWS)-Related Glaucoma Due to Elevated Episcleral Venous Pressure (EVP)
Actual Study Start Date : October 19, 2021
Actual Primary Completion Date : June 6, 2022
Actual Study Completion Date : August 1, 2022

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Glaucoma

Arms and Interventions
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm Intervention/treatment
Experimental: 1% QLS-101
dosed once a day for 14 days as either first or second dosing period per randomization
 Drug: QLS-101ophthalmic solution 1%
QLS-101ophthalmic solution 1.0%
Other Name: QLS-101
Experimental: 2% QLS-101
dosed once a day for 14 as either first or second dosing period per randomization
 Drug: QLS-101ophthalmic solution 2%
QLS-101ophthalmic solution 2.0%
Other Name: QLS-101


Outcome Measures
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. Ocular AEs [ Time Frame: 56 days, including a 14-day washout ]
    Standard safety endpoint, ocular AEs, (including elevated IOP)

  2. Visual acuity [ Time Frame: 56 days, including a 14-day washout ]
    Standard safety endpoint, best corrected visual acuity, Snellen score, change from baseline

  3. Enhance depth imaging optical coherence tomography (EDI-OCT) [ Time Frame: 56 days, including a 14-day washout ]
    Standard safety endpoint, EDI-OCT, corneal thickness

  4. Slit lamp exam [ Time Frame: 56 days, including a 14-day washout ]
    Standard safety endpoint, slit lamp exam, abnormalities, changes from baseline

  5. Dilated fundus exam [ Time Frame: 56 days, including a 14-day washout ]
    Fundus exam, abnormalities, changes from baseline


Secondary Outcome Measures :
  1. Ocular hypotensive efficacy [ Time Frame: 14 days after each dosing timepoint is completed ]
    Mean change in IOP from baseline following 14 days dosing


Eligibility Criteria
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Diagnosed with SWS.
  • Elevated intraocular pressure (IOP)
  • Willing to continue current dosing regimen of IOP-lowering medications
  • Willing to refrain from contact lens use in the study eye.

Exclusion Criteria:

  • IOP with variability of > 4 mm Hg
  • Expected to undergo IOP-lowering surgery
  • Incisional or laser surgery of any type
  • Ocular infection, inflammation, clinically significant blepharitis or conjunctivitis
  • A history of herpes simplex keratitis in either eye.
  • History of or active clinically significant ocular disease
  • Use of topical ocular corticosteroids in the 6 weeks prior to Visit 1
Contacts and Locations
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04947124


Locations
Layout table for location information
United States, North Carolina
Duke Eye Center
Durham, North Carolina, United States, 27710
Sponsors and Collaborators
Qlaris Bio, Inc.
More Information
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Additional Information:

Layout table for additonal information
Responsible Party: Qlaris Bio, Inc.
ClinicalTrials.gov Identifier: NCT04947124    
Other Study ID Numbers: QC-203
First Posted: July 1, 2021    Key Record Dates
Last Update Posted: August 23, 2022
Last Verified: July 2022
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Qlaris Bio, Inc.:
Sturge-Weber Syndrome
Glaucoma
Elevated IOP
Additional relevant MeSH terms:
Layout table for MeSH terms
Sturge-Weber Syndrome
Brain Stem Infarctions
Glaucoma
Ocular Hypertension
Hydrophthalmos
Klippel-Trenaunay-Weber Syndrome
Syndrome
Disease
Pathologic Processes
Vascular Diseases
Cardiovascular Diseases
Eye Diseases
Brain Infarction
Brain Ischemia
Cerebrovascular Disorders
 Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Stroke
Infarction
Ischemia
Necrosis
Angiomatosis
Hemangioma
Neoplasms, Vascular Tissue
Neoplasms by Histologic Type
Neoplasms
Neurocutaneous Syndromes
Eye Abnormalities
Glaucoma, Open-Angle